Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia

Schizophrenia Research

Volumn 120, Issue 1-3, 2010, Pages 101-107

  Sevy, Serge ^a,b   Robinson, Delbert G ^a,b,c   Napolitano, Barbara ^a,c   Patel, Raman C ^d   Gunduz Bruce, Handan ^e   Miller, Rachel ^f   McCormack, Joanne ^a   Lorell, Beth S ^d   Kane, John ^a,b,c  

^a Psychiatry Research ^*  (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d Bronx Lebanon Hospital   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Abuse; Cannabis; Dependence; First episode; Onset; Schizophrenia

Indexed keywords

ACADEMIC ACHIEVEMENT; ADULT; ARTICLE; CANNABIS ADDICTION; CONTROLLED STUDY; DELUSION; DISEASE ASSOCIATION; DISEASE SEVERITY; EDUCATION; FEMALE; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; ONSET AGE; POSITIVE SYNDROME; PRIORITY JOURNAL; SCHIZOPHRENIA; SOCIAL ADAPTATION; SOCIAL STATUS; ADOLESCENT; COMPLICATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EXECUTIVE FUNCTION; MARIJUANA ABUSE; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PHYSIOLOGY; PROSPECTIVE STUDY; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SHORT TERM MEMORY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE OF ONSET; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MEMORY, SHORT-TERM; NEUROPSYCHOLOGICAL TESTS; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

EID: 77954144489     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.03.037     Document Type: Article

References (68)

1. Addington J., Addington D. Impact of an early psychosis program on substance use. Psychiatry Rehabil. J. 2001, 25(1):60-67.
2. Allebeck P., Adamsson C., Engstrom A., et al. Cannabis and schizophrenia: a longitudinal study of cases treated in Stockholm County. Acta Psychiatr. Scand. 1993, 88(1):21-24.
3. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br. J. Psychiatry Suppl. 1989, 7:49-58.
4. Andreasson S., Allebeck P., Engstrom A., et al. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987, 2(8574):1483-1486.
5. Andreasson S., Allebeck P., Rydberg U. Schizophrenia in users and nonusers of cannabis. A longitudinal study in Stockholm County. Acta Psychiatr. Scand. 1989, 79(5):505-510.
6. Arndt S., Tyrrell G., Flaum M., et al. Comorbidity of substance abuse and schizophrenia: the role of pre-morbid adjustment. Psychol. Med. 1992, 22(2):379-388.
7. Arseneault L., Cannon M., Poulton R., et al. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. Br. Med. J. 2002, 325(7374):1212-1213.
8. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 1989, 154:672-676.
9. Barnes T.R., Mutsatsa S.H., Hutton S.B., et al. Comorbid substance use and age at onset of schizophrenia. Br. J. Psychiatry 2006, 188:237-242.
10. Barnett J.H., Werners U., Secher S.M., et al. Substance use in a population-based clinic sample of people with first-episode psychosis. Br. J. Psychiatry 2007, 190:515-520.
11. Basso M.R., Nasrallah H.A., Olson S.C., et al. Cognitive deficits distinguish patients with adolescent- and adult-onset schizophrenia. Neuropsychiatry Neuropsychol. Behav. Neurol. 1997, 10(2):107-112.
12. Bertelsen M., Jeppesen P., Petersen L., et al. Course of illness in a sample of 265 patients with first-episode psychosis - five-year follow-up of the Danish OPUS trial. Schizophr. Res. 2009, 107(2-3):173-178.
13. Blanchard J.J., Brown S.A., Horan W.P., et al. Substance use disorders in schizophrenia: review, integration, and a proposed model. Clin. Psychol. Rev. 2000, 20(2):207-234.
14. Breakey W.R., Goodell H., Lorenz P.C., et al. Hallucinogenic drugs as precipitants of schizophrenia. Psychol. Med. 1974, 4(3):255-261.
15. Buhler B., Hambrecht M., Loffler W., et al. Precipitation and determination of the onset and course of schizophrenia by substance abuse - a retrospective and prospective study of 232 population-based first illness episodes. Schizophr. Res. 2002, 54(3):243-251.
16. Cannon-Spoor H.E., Potkin S.G., Wyatt R.J. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr. Bull. 1982, 8(3):470-484.
17. Cantwell R., Brewin J., Glazebrook C., et al. Prevalence of substance misuse in first-episode psychosis. Br. J. Psychiatry 1999, 174:150-153.
18. Caspi A., Moffitt T.E., Cannon M., et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene×environment interaction. Biol. Psychiatry 2005, 57(10):1117-1127.
19. Chambers R.A., Krystal J.H., Self D.W. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol. Psychiatry 2001, 50(2):71-83.
20. Dean B., Sundram S., Bradbury R., et al. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001, 103(1):9-15.
21. Dixon L., Haas G., Weiden P.J., et al. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am. J. Psychiatry 1991, 148(2):224-230.
22. Drake R.J., Haley C.J., Akhtar S., et al. Causes and consequences of duration of untreated psychosis in schizophrenia. Br. J. Psychiatry 2000, 177:511-515.
23. Fenton W.S. Prevalence of spontaneous dyskinesia in schizophrenia. J. Clin. Psychiatry 2000, 61(Suppl 4):10-14.
24. Fernandez-Ruiz J. The endocannabinoid system as a target for the treatment of motor dysfunction. Br. J. Pharmacol. 2009, 156(7):1029-1040.
25. Frangou S., Hadjulis M., Vourdas A. The Maudsley early onset schizophrenia study: cognitive function over a 4-year follow-up period. Schizophr. Bull. 2008, 34(1):52-59.
26. Gfroerer J.C., Wu L.-T., Penne M.A. Initiation of marijuana use: trends, patterns, and implications, DHHS Publication No. SMA 02-3711, Analytic Series A-17. Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Rockville, MD Available at. http://www.oas.samhsa.gov/analytic.htm.
27. Giuffrida A., Parsons L.H., Kerr T.M., et al. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat. Neurosci. 1999, 2(4):358-363.
28. Green A.I., Tohen M.F., Hamer R.M., et al. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr. Res. 2004, 66(2-3):125-135.
29. Gunduz-Bruce H., Narr K.L., Gueorguieva R., et al. CSF sub-compartments in relation to plasma osmolality in healthy controls and in patients with first episode schizophrenia. Psychiatry Res. 2007, 155(1):57-66.
30. Hambrecht M., Hafner H. Substance abuse and the onset of schizophrenia. Biol. Psychiatry 1996, 40(11):1155-1163.
31. Hoff A.L., Harris D., Faustman W.O., et al. A neuropsychological study of early onset schizophrenia. Schizophr. Res. 1996, 20(1-2):21-28.
32. Hollingshead A.B., Redlich F.C. Social Class and Mental Illness; A Community Study 1958, Wiley, New York.
33. Honer W.G., Kopala L.C., Rabinowitz J. Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness. J Psychopharmacol 2005, 19(3):277-285.
34. Jeste D.V., McAdams L.A., Palmer B.W., et al. Relationship of neuropsychological and MRI measures to age of onset of schizophrenia. Acta Psychiatr. Scand. 1998, 98(2):156-164.
35. Kovasznay B., Fleischer J., Tanenberg-Karant M., et al. Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr. Bull. 1997, 23(2):195-201.
36. Lakhan S.E., Rowland M. Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. BMC Neurol. 2009, 9:59.
37. Linszen D.H., Dingemans P.M., Lenior M.E. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch. Gen. Psychiatry 1994, 51(4):273-279.
38. Loberg E.M., Hugdahl K. Cannabis use and cognition in schizophrenia. Front. Hum. Neurosci. 2009, 3:53.
39. Mauri M.C., Volonteri L.S., De Gaspari I.F., et al. Substance abuse in first-episode schizophrenic patients: a retrospective study. Clin. Pract. Epidemol. Ment. Health 2006, 2:4.
40. Muller-Vahl K.R., Schneider U., Koblenz A., et al. Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 2002, 35(2):57-61.
41. Muller-Vahl K.R., Schneider U., Prevedel H., et al. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J. Clin. Psychiatry 2003, 64(4):459-465.
42. Oie M., Hugdahl K. A 10-13year follow-up of changes in perception and executive attention in patients with early-onset schizophrenia: a dichotic listening study. Schizophr. Res. 2008, 106(1):29-32.
43. Pappa S., Dazzan P. Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review. Psychol. Med. 2009, 39(7):1065-1076.
44. Peralta, V., Campos, M. S., De Jalon, E. G., et al., Motor behavior abnormalities in drug-naive patients with schizophrenia spectrum disorders. Mov Disord.
45. Rabinowitz J., Bromet E.J., Lavelle J., et al. Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients. Psychol. Med. 1998, 28(6):1411-1419.
46. Ritzler B.A., Strauss J.S., Vanord A., et al. Prognostic implications of various drinking patterns in psychiatric patients. Am. J. Psychiatry 1977, 134(5):546-549.
47. Robinson D., Woerner M., Schooler N. Intervention research in psychosis: issues related to clinical assessment. Schizophr. Bull. 2000, 26(3):551-556.
48. Robinson D.G., Woerner M.G., Napolitano B., et al. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am. J. Psychiatry 2006, 163(12):2096-2102.
49. SAMHSA Results from the 2005 National Survey on Drug Use and Health: National Findings 2006, Office of Applied Studies, Rockville, MD.
50. Sevy S., Burdick K.E., Visweswaraiah H., et al. Iowa gambling task in schizophrenia: a review and new data in patients with schizophrenia and co-occurring cannabis use disorders. Schizophr. Res. 2007, 92(1-3):74-84.
51. Sevy S., Kay S.R., Opler L.A., et al. Significance of cocaine history in schizophrenia. J. Nerv. Ment. Dis. 1990, 178(10):642-648.
52. Sevy S., Robinson D.G., Holloway S., et al. Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatr. Scand. 2001, 104(5):367-374.
53. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970, 212:11-19.
54. Strakowski S.M., Tohen M., Stoll A.L., et al. Comorbidity in psychosis at first hospitalization. Am. J. Psychiatry 1993, 150(5):752-757.
55. Szymanski S., Lieberman J.A., Alvir J.M., et al. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am. J. Psychiatry 1995, 152(5):698-703.
56. Tanda G., Di Pontieri F.E., Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 1997, 276(5321):2048-2050.
57. Thaden E., Rhinewine J.P., Lencz T., et al. Early-onset schizophrenia is associated with impaired adolescent development of attentional capacity using the identical pairs continuous performance test. Schizophr. Res. 2006, 81(2-3):157-166.
58. Tsuang M.T., Simpson J.C., Kronfol Z. Subtypes of drug abuse with psychosis. Demographic characteristics, clinical features, and family history. Arch. Gen. Psychiatry 1982, 39(2):141-147.
59. Tuulio-Henriksson A., Partonen T., Suvisaari J., et al. Age at onset and cognitive functioning in schizophrenia. Br. J. Psychiatry 2004, 185:215-219.
60. Van Mastrigt S., Addington J., Addington D. Substance misuse at presentation to an early psychosis program. Soc. Psychiatry Psychiatr. Epidemiol. 2004, 39(1):69-72.
61. van Os J., Bak M., Hanssen M., et al. Cannabis use and psychosis: a longitudinal population-based study. Am. J. Epidemiol. 2002, 156(4):319-327.
62. Veen N.D., Selten J.P., van der Tweel I., et al. Cannabis use and age at onset of schizophrenia. Am. J. Psychiatry 2004, 161(3):501-506.
63. Wade D., Harrigan S., Edwards J., et al. Course of substance misuse and daily tobacco use in first-episode psychosis. Schizophr. Res. 2006, 81(2-3):145-150.
64. Wade D., Harrigan S., Edwards J., et al. Substance misuse in first-episode psychosis: 15-month prospective follow-up study. Br. J. Psychiatry 2006, 189:229-234.
65. Weiser M., Knobler H.Y., Noy S., et al. Clinical characteristics of adolescents later hospitalized for schizophrenia. Am. J. Med. Genet. 2002, 114(8):949-955.
66. White T., Ho B.C., Ward J., et al. Neuropsychological performance in first-episode adolescents with schizophrenia: a comparison with first-episode adults and adolescent control subjects. Biol. Psychiatry 2006, 60(5):463-471.
67. Woodberry K.A., Giuliano A.J., Seidman L.J. Premorbid IQ in schizophrenia: a meta-analytic review. Am. J. Psychiatry 2008, 165(5):579-587.
68. Zammit S., Allebeck P., Andreasson S., et al. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. Br. Med. J. 2002, 325(7374):1199.